Advertisement
Novartis
Subscribe to Novartis

The Lead

FDA Recommends Approval of Novartis’ AIN457 (secukinumab) for Moderate-to-Severe Plaque Psoriasis

October 20, 2014 3:28 pm | News | Comments

Novartis announced the Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) to the FDA voted 7 to 0 to support the approval of AIN457, a selective interleukin-17A inhibitor, for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

Novartis Says Three Members of Executive Committee to Leave Company

October 8, 2014 9:09 am | News | Comments

Novartis confirmed today that following completion of the transactions with GlaxoSmithKline and...

EU OKs Eli Lilly's $5.4B Bid for Novartis division

October 3, 2014 6:47 am | by The Associated Press | News | Comments

The European Union's antitrust authority says it has approved the $5.4 billion sale of Novartis...

Center for Advanced Cellular Therapeutics to Rise on Penn Medicine Campus

September 12, 2014 8:09 am | News | Comments

The University of Pennsylvania today reached an important milestone in its alliance with...

View Sample

FREE Email Newsletter

Merus Labs Acquire Sintrom from Novartis

September 8, 2014 8:49 am | News | Comments

Merus Labs International has acquired from Novartis AG, in certain European countries, the rights to manufacture, market, and sell the branded prescription medicine product Sintrom® (acenocoumarol).          

Ophthotech Achieves $50M Milestone under Ex-US Licensing and Commercial Agreement with Novartis for Fovista®

September 8, 2014 8:07 am | News | Comments

Ophthotech Corporation today announced that it has achieved a $50 million enrollment milestone payment from Novartis Pharma AG as part of the ex-US licensing and commercialization agreement between the two companies focused on the treatment of wet age-related macular degeneration (AMD).

FDA Reviewing What Could Be First Biosimilar Drug

July 24, 2014 3:51 pm | News | Comments

Five years after Congress passed a law allowing biosimilars, for the first time the FDA has accepted an application to sell a similar, but not identical, version of a biologic drug.            

Advertisement

Novartis Cites Momentum in 3% Profit Rise

July 17, 2014 2:30 am | by The Associated Press | News | Comments

Novartis AG says its second-quarter profit rose 3 percent from a year earlier, reflecting solid growth and an increased focus on core products. The Basel-based company reports that profit during the April-June quarter rose to $3.28 billion, up from $3.18 billion in the same quarter of 2013.

Like Peanut Butter and Chocolate

July 16, 2014 3:02 pm | by Mike Auerbach, Editor In Chief | Blogs | Comments

Some things just seem to naturally go together – peanut butter and chocolate is one of those combinations – especially in the form of peanut butter cups. Bacon and eggs is another, as is peanut butter and jelly, pizza and beer and numerous other tasty combinations.

Novartis to Use Google Technology for Eye Care

July 15, 2014 8:51 am | by The Associated Press | News | Comments

The drugmaker said its Alcon eye care division will license Google technology and work with a team from Google to develop a lens that uses microchips and miniaturized electronics.            

Incyte Get $25M Milestone Payment from Novartis after Jakavi® Approval in Japan

July 8, 2014 9:01 am | News | Comments

Incyte Corporation announced today that it has earned a $25 million milestone payment from Novartis in connection with the approval of Jakavi® (ruxolitinib) in Japan for the treatment of patients with myelofibrosis.      

Novartis Personalized Cell Therapy CTL019 Receives FDA Breakthrough Therapy Designation

July 7, 2014 3:18 pm | News | Comments

Novartis announced that the FDA has granted Breakthrough Therapy status to CTL019, an investigational chimeric antigen receptor (CAR) therapy for the treatment of pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL).

Advertisement

Ex-Novartis Pharma Employee Arrested Over Drug Data

June 11, 2014 8:19 am | News | Comments

Tokyo prosecutors arrested a former employee of Novartis Pharma K.K. on Wednesday on a charge of manipulating clinical study data leading to exaggerated claims in advertising for one of the firm's drugs.        

Italy Seeks $1.6B in Damages from Novartis and Roche

May 29, 2014 1:45 pm | News | Comments

Italy's health ministry is seeking 1.2 billion euros ($1.63 billion) in damages from Swiss pharmaceutical giants Novartis and Roche after an anti-trust court ruled the two companies colluded to prevent the distribution of an eye medication.  

Meningococcal Vaccine Market Expected To Hit $3.76B By 2019

May 9, 2014 9:34 am | News | Comments

According to a new report published by Transparency Market Research, "Meningococcal Vaccines Market - Global Industry Analysis 2013 - 2019," the market for meningococcal vaccines was valued at USD 1.5 billion in 2012 and is expected to reach a value of USD 3.7 billion in 2019, growing at a CAGR of 14.9% from 2013 to 2019.

FDA Approves Zykadia for Late-Stage Lung Cancer

April 29, 2014 4:16 pm | News | Comments

The FDA has granted accelerated approval to Zykadia (ceritinib) for patients with a certain type of late-stage (metastatic) non-small cell lung cancer (NSCLC). Zykadia is an anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor that blocks proteins that promote the development of cancerous cells.

Deal Flurry Shows Drug Makers’ Move to Specialization

April 24, 2014 8:58 am | Videos | Comments

The recent flurry of drug deals shows how the global pharmaceutical industry is reversing course, as companies narrow their focus after decades of diversifying their drug portfolios.            

Advertisement

New Drug Sales Help Boost Novartis First Quarter Profit

April 24, 2014 5:30 am | by John Heilprin - Associated Press - Associated Press | News | Comments

Strong new drug sales helped Novartis AG report a 24 percent rise in first-quarter profit. The company said Thursday that its net profit of nearly $2.97 billion, which was up from $2.42 billion in the same period last year, was helped by sales growth from some of its newwst product launches.

Investor Pressure Pushing Pharmaceutical M&A Deals

April 22, 2014 7:31 pm | by Linda A. Johnson - AP Business Writer - Associated Press | News | Comments

Drugmakers eager to satisfy shareholders by boosting profits and share prices are wheeling, dealing and in one case even making trades like a pro sports team looking to shake up its roster. The moves could spur more mergers and acquisitions in the industry.

Novartis and Glaxo Deal Reshapes Pharma Industry

April 22, 2014 8:58 am | Videos | Comments

Novartis completed about $25 billion of transactions in its product portfolios, including the sale of two units to British-based GlaxoSmithKline. The WSJ explains why the Swiss company is doing these deals now and what this means for the pharmaceutical industry.

Novartis, GSK, Lilly in Multibillion-Dollar Deals

April 22, 2014 4:28 am | by John Heilprin - Associated Press - Associated Press | News | Comments

Swiss pharmaceutical giant Novartis AG announced a series of multibillion-dollar deals Tuesday with other major pharmaceutical companies that it said would reduce sales but boost profitability, while affecting some 15,000 of its employees globally.

Novartis Top Management Quits Over Involvement in Clinical Study

April 3, 2014 8:04 am | News | Comments

Novartis Pharma K.K. said Thursday its president Yoshiyasu Ninomiya and two other top executives have resigned to take responsibility for its employees' inappropriate involvement in a clinical study led by medical doctors.     

Effectiveness Prompts Novartis to End Drug Study

March 31, 2014 10:26 am | by The Associated Press | News | Comments

Novartis said it's cutting off late-stage research into a potential chronic heart failure treatment because the drug has proven so effective, sending shares to an all-time high when markets opened today.        

FDA Approves Xolair for Chronic Idiopathic Urticaria

March 24, 2014 8:25 am | News | Comments

The FDA has approved Xolair (omalizumab) for the treatment of chronic idiopathic urticaria (CIU), a form of chronic hives. The new use is for patients 12 years of age and older who remain symptomatic despite treatment with H1-antihistamine therapy.

Novartis Provides Second US University with Bexsero

February 24, 2014 8:16 am | News | Comments

Novartis announced today that its meningococcal serogroup B (MenB) vaccine, Bexsero (Meningococcal Group B Vaccine [rDNA, component, adsorbed]), will be used as part of a vaccination program at the University of California Santa Barbara (UCSB) that began today and will end on March 7.

Novartis Case Linked to Structural Problems Between Doctors, Industry

February 20, 2014 8:02 am | News | Comments

The manipulation of clinical research data for a blood pressure drug sold by Novartis Pharma K.K. has led a special squad of Tokyo prosecutors to search the Japanese unit of the Swiss drugmaker as well as the university that conducted the research.

Tokyo Prosecutors Raid Novartis Pharma Over Drug Ads

February 19, 2014 8:01 am | News | Comments

Tokyo prosecutors raided Novartis Pharma K.K. on Wednesday over its alleged use of exaggerated advertising for a blood pressure-lowering drug, following a criminal complaint filed by the health ministry last month.       

CoStim Pharmaceuticals Acquired by Novartis

February 18, 2014 8:27 am | News | Comments

CoStim, founded in 2012 by MPM Managing Director Luke Evnin together with MPM Managing Director-Operations Robert Millman, is an emerging immuno-oncology company developing monoclonal antibody drugs that enable a patient's own immune system to better fight cancer.

Novartis Fourth Quarter Net Profit Rises to $2.0B

January 29, 2014 3:13 am | by John Heilprin - Associated Press - Associated Press | News | Comments

Novartis AG reported a 2 percent rise in fourth-quarter net profit Wednesday, helped by delays in generic competition to its blockbuster drugs. The Basel, Switzerland-based company said it had a net profit of $2.029 billion attributable to shareholders in the final three months of 2013.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading